Bluebird Bio Inc. priced its underwritten public offering of 3,243,244 shares at $185 per share, with plans to raise about $600 million.
The company granted the underwriters a 30-day option to purchase up to an additional 486,486 shares.
Bluebird Bio expects to raise approximately $600 million in gross proceeds from the offering, excluding any exercise of the underwriters' option to purchase additional shares.
The offering is expected to close on or about Dec. 15, subject to customary closing conditions.
Goldman Sachs & Co. LLC, Bank of America Merrill Lynch, J.P. Morgan Securities LLC and Cowen are acting as joint book-running managers of the offering.
